![GSK, Novartis top Access to Medicine ranking with pricing, R&D initiatives | S&P Global Market Intelligence GSK, Novartis top Access to Medicine ranking with pricing, R&D initiatives | S&P Global Market Intelligence](https://www.snl.com/articles/395847134.png)
GSK, Novartis top Access to Medicine ranking with pricing, R&D initiatives | S&P Global Market Intelligence
![GlobalData's Top 20 global pharmaceutical companies by market cap (year ended December 31, 2018) - GlobalData GlobalData's Top 20 global pharmaceutical companies by market cap (year ended December 31, 2018) - GlobalData](https://eu.vocuspr.com/Publish/3434416/vcsPRAsset_3434416_101379_2e746a63-4a5f-4c53-a839-000a1e75a721_0.png)
GlobalData's Top 20 global pharmaceutical companies by market cap (year ended December 31, 2018) - GlobalData
![GlobalData's Top 20 global pharmaceutical companies by market cap (year ended December 31, 2018) - GlobalData GlobalData's Top 20 global pharmaceutical companies by market cap (year ended December 31, 2018) - GlobalData](https://eu.vocuspr.com/Publish/3434416/vcsPRAsset_3434416_101380_a53786a6-9ceb-48f2-8411-276c2e1b6478_0.png)
GlobalData's Top 20 global pharmaceutical companies by market cap (year ended December 31, 2018) - GlobalData
![JP Morgan tops GlobalData's ranking of financial advisers in healthcare M&As - Pharmaceutical Technology JP Morgan tops GlobalData's ranking of financial advisers in healthcare M&As - Pharmaceutical Technology](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2018/08/Top-20-League-Tables_Financial-and-Legal-01-e1533725924355.jpg)